FIELD: organic chemistry, chemical technology, medicine, biochemistry, pharmacy.
SUBSTANCE: invention relates to new crystalline hydrated form of bis-[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidine-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt of the formula (I):
having powder roentgenogram with specific peaks at value of angle 2θ = 4.92; 11.50; 6.93; 9.35; 23.12 and 18.76o. These compounds can be used for preparing medicinal preparation eliciting properties of HMG-CoA-reductase inhibitor. Method for preparing indicated salt involves formation of crystals from a mixture of compound of the formula (I), water and organic solvent taken among acetonitrile, acetone or a mixture of methanol and methyl-tert.-butyl ester. Invention relates also to a pharmaceutical composition and a method for it preparing, and to a method for treatment of morbidity state when inhibition of activity of HMG-CoA-reductase is useful.
EFFECT: improved preparing methods, valuable medicinal and biochemical properties of salt.
6 cl, 2 dwg, 1 ex
| Title |
Year |
Author |
Number |
| 7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- [METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN -5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID CRYSTALLINE SALTS, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION |
2001 |
- Tehjlor Najdzhel Filip
- Okada Tetsuo
|
RU2265599C2 |
| CRYSTALLINE FORM OF CALCIUM SALT OF BIS-[(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULPHONYL)AMINO]-PYRIMIDIN-5-YL](3R, 5S)-3, 5-DIHYDROXYHEPT-6-ENOIC ACID |
2004 |
- But Rebekka Dzhejn
- Sittern Piter Ehntoni
- Krabb Dzheffri Norman
- Khorberi Dzhon
- Dzhouns Dejvid Uin Kalvert
|
RU2363697C2 |
| METHOD OF PRODUCING ROSUVASTATIN CALCIUM SALT (E) -7-[4-(4-FLUOROPHEHYL)-6-ISOPROPYL-2-[METHYL(METHYLSULPHONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND CRYSTALLINE INTERMEDIATE PRODUCTS THEREOF |
2004 |
- Okada Tetsuo
- Khorberi Dzhon
- Laffan Dejvid Dermot Patrik
|
RU2372349C2 |
| APPLICATION OF 3-HYDROXY-3-METHTYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS IN PRODUCING MEDICINAL AGENT FOR TREATMENT OF DIABETIC NEUROPATHY |
2000 |
- Kehmeron Norman Judzhin
- Kotter Mehri Ehnn
|
RU2239456C2 |
| METHOD OF PRODUCTION OF MEVALONIC ACID DERIVATIVES INHIBITING HMG-COA REDUCTASE |
2003 |
- Zedel'Majer Gottfrid
- Mates Kristian
|
RU2335500C2 |
| TERTIARY BUTYL-(E)-(6-{2-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL}-(4R,6S)-2,2-DIMETHYL[1,3]DIOXANE-4-YL]ACETATE AND METHOD FOR ITS PREPARING, DIPHENYL-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YLMETHYL]PHOSPHINE OXIDE, METHODS FOR PREPARING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND ITS DERIVATIVES |
2000 |
- Koike Kharuo
- Kabaki Mikio
- Tehjlor Najdzhel Filip
- Dioratsio Lui Dzhozef
|
RU2243969C2 |
| METHOD OF PRODUCING N-[5-(3,5-DIFTORBENZIL)-1H-INDAZOLE-3-YL]-4-(4-METHYLPIPERAZINE-1-YL)-2-(TETRAHYDROPYRAN-4-YLAMINO)BENZAMIDE |
2013 |
- Barbudzhan Natale Alvaro
- Forino Romualdo
- Orsini Paolo
|
RU2602071C2 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITOR OF HMG-REDUCTASE |
2000 |
- Krikmor Dzhozef Richard
- Uigginz Norman Al'Fred
|
RU2206324C1 |
| CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-{ 6-[4-(4-ETHYLPIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL} -1-METHYLUREA AND ITS FRACTIONS |
2010 |
- Jerg Bergkhauzen
- Prasad Kotesvara Kapa
- Dzhozef Makkenna
- Dzhoehl Slejd
- Rejann Vu
- Chzhehnmin Du
- Frank Shtovasser
|
RU2572848C2 |
| METHOD OF PRODUCING CALCIUM SALT (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROYL-2-[METHYL(METHYSUFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)3,5-DIHYDROXYHEPT-6-ENOIC ACID (ROSUVASTATIN CALCIUM SALT) |
2004 |
- Krabb Dzheffri Norman
- Khorberi Dzhon
- Tejlor Najdzhel Filip
|
RU2361864C2 |
